Clay Siegall
Clay Siegall is President and CEO at Immunome. He was President and CEO at Morphimmune and SeaGen. He is a Board Member at Shattuck Labs and was Chairman at Tourmaline Bio.
Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics
Clay Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food andDrug Administration (FDA) in 2011. Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997…
Organizations
See all 5-
Immunome President and CEO 2023–present · current
-
Shattuck Labs Board Member 2024–present · current
-
Tourmaline Bio Chairman 2023–2025 · past
Education
-
The George Washington University Doctor of Philosophy - PhD, Genetics
-
University of Maryland Bachelor of Science - BS, Zoology